ASCO abstracts lead to one big pop and one big drop
With the release of ASCO abstracts, essentially a huge clinical trial data release ahead of the annual cancer conference, we witnessed a few pops and drops among biotech stocks.
In this video, healthcare analyst David Williamson takes a closer look at two stocks seeing 20% moves -- Oncothyreon (NASDAQ: ONTY) and Halozyme (HALO -1.69%) -- and discusses what these events mean for investors.
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
